Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Pharmacology

Background:

• Tuberculosis (TB) drug discovery was a 20th-century milestone, but drug resistance emerged early.
• Multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB affect 450,000 individuals annually, causing 4000 daily deaths.
• Existing TB treatments require improvement in efficacy, dosage, and toxicity to enhance patient compliance and quality of life.

Purpose of the Study:

• To explore the potential of inhaled aerosol drug delivery as a strategy to improve existing tuberculosis treatments.
• To highlight the untapped opportunity of inhaled therapies for pulmonary Mycobacterium tuberculosis (Mtb) infections.

Main Methods:

• This study is a review and strategic proposal, not an experimental investigation.
• It analyzes the current landscape of TB treatment and drug resistance.
• It proposes inhaled aerosol delivery as a novel therapeutic approach.

Main Results:

• Inhaled drug delivery is established for other pulmonary diseases but not yet for TB.
• Targeting the lung directly via inhalation offers potential for improved drug efficacy and reduced systemic toxicity.
• This approach could significantly improve outcomes for patients with drug-susceptible and drug-resistant TB.

Conclusions:

• Prioritizing the enhancement of existing TB drugs is essential while pursuing new treatments and vaccines.
• Inhaled aerosol therapy represents a viable and underutilized strategy to improve the efficacy and safety of TB medications.
• The pharmaceutical, clinical, and regulatory sectors should actively consider and develop inhaled therapies for TB treatment.